Skip to content

Simone Pardossi

4 papers in the library · 63 citations · publishing 2024-2026

Papers

Sort Most recent Most cited

Intranasal esketamine in treatment-resistant depression: long-term dosing patterns and clinical outcomes in a 5-year observational study.

Therapeutic Advances in Psychopharmacology 2026 Alessandro Cuomo, Roger S McIntyre, Despoina Koukouna et al. 1 citation

Treatment-resistant depression (TRD) remains a major clinical challenge, and long-term real-world data on intranasal esketamine are limited. To describe long-term dosing patterns and clinical outcomes associated with intranasal esketamine in routine clinical practice. Single-center observational cohort study with descriptive analyses. We analyzed 45 patients with TRD treated with intranasal...

DOI: 10.1177/20451253261437597 (opens in new tab) Full text (opens in new tab) Esketamine Treatment-resistant depression Madrs Dosing patterns +6

Symptom modulation and tolerability of intravenous ketamine in treatment-resistant bipolar depression: A retrospective study.

Journal of Affective Disorders May 1, 2025 Alessandro Cuomo, Simone Pardossi, Giovanni Barillà et al. 7 citations

Ketamine's use in treating bipolar depression must account for risks, such as switching to manic episodes or worsening symptoms. This study examines ketamine's impact on depressive symptoms, focusing on 'inner tension,' 'sleep reduction,' and 'suicidal ideation' over four weeks in treatment-resistant bipolar disorder (TR-BD) patients. Fifty-nine patients with TR-BD were treated consecutively...

DOI: 10.1016/j.jad.2025.01.059 (opens in new tab) Full text (opens in new tab) Bipolar disorder Mental health treatment Ketamine therapy Bipolar depression +2

Variations in BDNF and Their Role in the Neurotrophic Antidepressant Mechanisms of Ketamine and Esketamine: A Review.

International Journal of Molecular Sciences December 5, 2024 Simone Pardossi, Andrea Fagiolini, Alessandro Cuomo 43 citations

Brain-derived neurotrophic factor (BDNF) is critical for neuroplasticity, synaptic transmission, and neuronal survival. Studies have implicated it in the pathophysiology of depression, as its expression is significantly reduced in brain areas such as the prefrontal cortex and hippocampus in patients with depression. Our narrative review focuses on the relationship between BDNF, ketamine, and...

DOI: 10.3390/ijms252313098 (opens in new tab) Full text (opens in new tab) Esketamine Major depressive disorder Treatment-resistant depression Bdnf +5

A Systematic Review on Ketamine and Esketamine for Treatment-Resistant Depression and Suicidality in Adolescents: A New Hope?

Children (Basel, Switzerland) June 29, 2024 Simone Pardossi, Andrea Fagiolini, Simona Scheggi et al. 12 citations

Treating depression in adolescents is a significant challenge, and major depressive disorder (MDD) with suicidal ideation and treatment-resistant depression (TRD) are common and potentially devastating to optimal psychological and physical development in this age group. Suicide is among the leading causes of youth mortality, and TRD occurs in up to 40% of adolescents with MDD. TRD involves...

DOI: 10.3390/children11070801 (opens in new tab) Full text (opens in new tab) Treatment-resistant depression Psychedelic therapy Adolescent depression Suicidal ideation +5